Kim TW - Search Results

1

Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer.

Shin SJ, Jeong JH, Park YS, Lee KH, Shim BY, Kim TW, Oh DY, Lee MA, Kim YT, Kim YH, Zang DY, Roh JK, Ahn JB. Shin SJ, et al. Among authors: kim yh, kim tw, kim yt. Invest New Drugs. 2011 Oct;29(5):1073-80. doi: 10.1007/s10637-010-9418-2. Epub 2010 Mar 21. Invest New Drugs. 2011. PMID: 20306116

2

Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.

Kim TW, Kang HJ, Ahn JH, Lee K, Chang HM, Kang YK, Lee JS. Kim TW, et al. Acta Oncol. 2002;41(7-8):689-94. doi: 10.1080/028418602321028328. Acta Oncol. 2002. PMID: 14651215 Clinical Trial.

3

Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.

Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR, Kim HK; Korean Cancer Study Group. Kim TW, et al. Among authors: kim sr, kim hk. Acta Oncol. 2005;44(3):230-5. doi: 10.1080/02841860510029590. Acta Oncol. 2005. PMID: 16076694 Clinical Trial.

4

A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.

Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Lee SS, Kim MK, Sym SJ, Lee JS, Kang YK. Koo DH, et al. Among authors: kim tw, kim mk. J Korean Med Sci. 2007 Sep;22 Suppl(Suppl):S98-S103. doi: 10.3346/jkms.2007.22.S.S98. J Korean Med Sci. 2007. PMID: 17923763 Free PMC article. Clinical Trial.

5

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS. Kang BW, et al. Among authors: kim tw, kim jc, kim jh. Med Oncol. 2009;26(1):32-7. doi: 10.1007/s12032-008-9077-8. Epub 2008 May 22. Med Oncol. 2009. PMID: 18498064

6

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.

Lee J, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh DY, Shin DB, Kim TW, Lee N, Byun JH, Hong YS, Park JO, Park SH, Lim HY, Kang WK. Lee J, et al. Among authors: kim tw. Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63. doi: 10.1007/s00280-008-0913-5. Epub 2009 Jan 24. Cancer Chemother Pharmacol. 2009. PMID: 19169686 Clinical Trial.

7

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK. Ryu MH, et al. Among authors: kim tw, kim ty, kim mk. Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. Oncology. 2009. PMID: 19307738 Clinical Trial.

8

Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors.

Kim TW, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM, Park YS, Lee KH, Kang WK, Shin DB, Bang YJ, Lee JS, Kang YK. Kim TW, et al. Oncologist. 2009 May;14(5):540-7. doi: 10.1634/theoncologist.2008-0145. Epub 2009 May 2. Oncologist. 2009. PMID: 19411681 Free article.

9

The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.

Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS. Sohn BS, et al. Among authors: kim tw, kim jc. Oncology. 2009;77(3-4):224-30. doi: 10.1159/000236046. Epub 2009 Sep 7. Oncology. 2009. PMID: 19738388

10

Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.

Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK. Sym SJ, et al. Among authors: kim bs, kim tw. Cancer Chemother Pharmacol. 2010 Jul;66(2):373-80. doi: 10.1007/s00280-009-1171-x. Epub 2009 Nov 21. Cancer Chemother Pharmacol. 2010. PMID: 19936751 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,592 results

Search Page

Filters